We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Third Wave and Mitsubishi Announce Japanese Joint Venture for Personalized Medicine
News

Third Wave and Mitsubishi Announce Japanese Joint Venture for Personalized Medicine

Third Wave and Mitsubishi Announce Japanese Joint Venture for Personalized Medicine
News

Third Wave and Mitsubishi Announce Japanese Joint Venture for Personalized Medicine

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Third Wave and Mitsubishi Announce Japanese Joint Venture for Personalized Medicine "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Third WaveTechnologies has formed a joint venture with Mitsubishi Corporation to accelerate the development and commercialization of clinical molecular diagnostic products and pharmacogenetics in Japan and throughout the Asia-Pacific region.

Third Wave Japan will accelerate and expand the development of high-value clinical products for the Japanese molecular diagnostic market, in particular, and the approval of those products by the Japanese Pharmaceuticals and Medical Devices Agency, or PDMA.

Products for hepatitis B and C viral load and genotyping, human papilloma virus, and mycobacterium are in development. In addition to these infectious disease products, Third Wave Japan anticipates developing pharmacogenetic products to improve drug safety and efficacy.

Third Wave will have worldwide rights outside the Asia-Pacific region to any new technology or product developed by Third Wave Japan.

"We are delighted to be partnering with Third Wave in Japan during this period of rapid change in the Japanese medical scene, during which technology advancement is opening new opportunities in diagnostics," said Tsunehiko Yanagihara, general manager of Mitsubishi Corporation's Life Sciences Business Unit.

Advertisement